Ikarian Capital’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Ikarian Capital’s Portfolio ISEE Stock Details ISEE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-437,900	Closed	-$7.86M	–	117
2022 Q3	$7.86M	Buy	437,900 +193,500	+79%	+$2.54M	1.57%	21
2022 Q2	$2.35M	Buy	+244,400	New	+$3.07M	0.43%	54
2021 Q4	–	Sell	-200,000	Closed	-$3.25M	–	242
2021 Q3	$3.25M	Buy	+200,000	New	+$2.18M	0.23%	98

Other funds holding ISEE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Ikarian Capital's ISEE Position: Q2 2023 in Review

Ikarian Capital sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2023, closing a stake of 213,521 shares — an estimated $5.19M sold.

Ikarian Capital first reported a position in ISEE in Q3 2021 and held it in 7 quarters. The position peaked at $17.6M in Q3 2022. 256 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.

Ikarian Capital reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ikarian Capital sold 213,521 IVERIC bio, Inc. Common Stock shares in Q2 2023, an estimated $5.19M.
Ikarian Capital first reported a position in IVERIC bio, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Ikarian Capital's IVERIC bio, Inc. Common Stock position peaked at $17.6M in Q3 2022.
256 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.